Compound A inhibits urothelial tumorigenesis via both the androgen receptor and glucocorticoid receptor signaling pathways.
Anti-androgen
dexamethasone
malignant transformation
prednisone
urothelial cancer
Journal
American journal of translational research
ISSN: 1943-8141
Titre abrégé: Am J Transl Res
Pays: United States
ID NLM: 101493030
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
11
2019
accepted:
20
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
9
6
2020
Statut:
epublish
Résumé
Recent preclinical evidence has indicated that both androgen receptor (AR) inactivation and glucocorticoid receptor (GR) transrepression are associated with suppression of urothelial carcinogenesis. We therefore assessed the effect of a unique compound, 2-(4-acetoxyphenyl)-2-chloro-N-methylethylammonium chloride (Compound A; CpdA), which could function as an AR antagonist as well as a GR ligand, on urothelial tumorigenesis. Using the
Types de publication
Journal Article
Langues
eng
Pagination
1779-1788Informations de copyright
AJTR Copyright © 2020.
Déclaration de conflit d'intérêts
None.
Références
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15827-32
pubmed: 16243974
Am J Cancer Res. 2014 Sep 06;4(5):461-73
pubmed: 25232488
Am J Cancer Res. 2018 Nov 01;8(11):2325-2336
pubmed: 30555747
Mol Cancer Ther. 2018 Jun;17(6):1303-1314
pubmed: 29592878
Mol Cancer Ther. 2012 Dec;11(12):2621-32
pubmed: 23033490
Mol Cell Endocrinol. 2018 Apr 15;465:73-81
pubmed: 28652170
Carcinogenesis. 1988 Aug;9(8):1427-36
pubmed: 2841047
J Urol. 2017 Feb;197(2):308-313
pubmed: 27506696
Cancer Biol Ther. 2016 Nov;17(11):1188-1196
pubmed: 27635763
Mol Cell Endocrinol. 2007 Sep 15;275(1-2):109-17
pubmed: 17630119
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Cancer. 2015 Feb 15;136(4):E27-38
pubmed: 25138562
Endocr Connect. 2018 Dec 1;7(12):1397-1408
pubmed: 30521479
Int J Cancer. 2005 Dec 10;117(5):866-72
pubmed: 15981214
Am J Clin Pathol. 2014 Aug;142(2):157-64
pubmed: 25015855
Mol Cell Endocrinol. 2013 Nov 5;380(1-2):41-54
pubmed: 23267834
Oncotarget. 2016 Mar 22;7(12):14153-60
pubmed: 26885620
J Urol. 2016 Oct;196(4):1021-9
pubmed: 27317986
Mol Endocrinol. 2015 Oct;29(10):1486-97
pubmed: 26322830
Mol Carcinog. 2013 Feb;52(2):94-102
pubmed: 22086872
Mol Endocrinol. 2014 Jul;28(7):999-1011
pubmed: 24766141
Oncotarget. 2014 Dec 30;5(24):12665-74
pubmed: 25557268
Am J Cancer Res. 2017 Oct 01;7(10):2041-2050
pubmed: 29119053
Cancer Chemother Pharmacol. 2014 Aug;74(2):249-55
pubmed: 24880571
Am J Pathol. 2013 May;182(5):1811-20
pubmed: 23499463
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518063
Mol Cell Endocrinol. 2003 Mar 28;201(1-2):155-64
pubmed: 12706303
Mol Carcinog. 2019 Dec;58(12):2297-2305
pubmed: 31535408
J Natl Cancer Inst. 2007 Apr 4;99(7):558-68
pubmed: 17406000